Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-104
- Development stage
- Preclinical
- Lead developer
- Dewcell Biotherapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
DCB-104 is an engineered artificial platelet cell therapy being developed by Dewcell Biotherapeutics for the treatment of drug-induced thrombocytopenia (DITP). Utilizing Dewcell's proprietary 'en-aPLT' platform, the therapy is designed to produce standardized, high-quality artificial platelets from human induced pluripotent stem cells (hiPSCs). This approach aims to overcome the limitations of donor-derived platelet transfusions, such as short shelf-life and supply shortages, by providing a scalable and donor-independent therapeutic option. DCB-104 is currently in the preclinical stage of development.
- Other names
- DITP
Beyond the preview
Go deeper on DCB-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-104.